Copyright© Ionis Pharmaceuticals, Inc. 1999-2019. All rights reserved.
This website includes forward-looking statements regarding Ionis Pharmaceuticals’ financial position and outlook, Ionis’ business, and the therapeutic and commercial potential of Ionis’ technologies and products in development. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis’ programs are described in additional detail in Ionis’ annual report on Form 10-K for the year ended December 31, 2017 and quarterly reports on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from each company.
In December, 2015, the Company changed its name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc. In this Web site, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals, Inc. hereby authorizes you to copy documents published by Ionis Pharmaceuticals, Inc. on the World Wide Web for non-commercial use within your organization only, provided any copy of these documents which you make shall retain all copyright and other proprietary notices contained herein. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of Ionis Pharmaceuticals, Inc. or any third party. Except as expressly provided above nothing contained herein shall be construed as conferring any license or right under any Ionis Pharmaceuticals, Inc. copyright.
This publication is provided “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.
Should you view an Ionis Pharmaceuticals, Inc. published document and respond with information including feedback data, such as questions, comments, suggestions, or the like regarding the content of any such Ionis Pharmaceuticals, Inc. document, such information shall be deemed to be non-confidential and Ionis Pharmaceuticals, Inc. shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose and distribute the information to others without limitation. Ionis Pharmaceuticals, Inc. shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.
Social media disclosure
Investors and others should note that Ionis will announce material, financial and operational information to its investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. In addition, Ionis also intends to use the @ionispharma (https://twitter.com/ionispharma) and the Ionis LinkedIn (https://www.linkedin.com/company/ionis-pharmaceuticals) accounts as a means to disclose information about Ionis and its products, pipeline and technology. Accordingly, investors should monitor @ionispharma and the Ionis LinkedIn accounts in addition to following Ionis press releases, SEC filings and public conference calls and webcasts. The social media channels that Ionis intends to use as a means of disclosing the information described above may be updated from time to time on Ionis’ website.